Introduction
============

Acute kidney injury is an abrupt loss of the kidney function characterized by an acute increase in serum creatinine concentration ([@B1]). Previousstudies ([@B2],[@B3]) revealed that even a mild increase in serum creatinine levels following cardiac surgery is associated with progression of chronic kidney disease and increased mortality. CSA-AKI is a common and severe complication in patients undergoing cardiac surgery and is associated with poor outcomes ([@B4]-[@B6])

At present, there are three widely accepted and used consensus definitions providing uniform criteria for the diagnosis of AKI, comparisons between studies, and the development of quantitative research. In 2004, the risk-injury-failure-loss-end-stage kidney disease (RIFLE) classification was developed by the Acute Dialysis Quality Initiative Group ([@B7]) and then improved by the Acute Kidney Injury Network (AKIN) in 2005 ([@B8]). In 2012, a modified definition, harmonized and not balancing the limitations of the AKIN and RIFLE, was established by the Kidney Disease: Improving Global Outcomes (KDIGO) group ([@B1]).

The incidence of AKI as well as management practices differ based on the definition of AKI ([@B9]). Furthermore, the definition of AKI also influences the identification of risk variables and independent predictors ([@B10]).While post-cardiac surgery AKI had been extensively studied before the establishment of KDIGO criteria ([@B11]-[@B13]) and has also been touched on recently by several studies using the KDIGO criteria ([@B14],[@B15]), it has not been fully investigated. In addition, the postoperative body temperature and potential protective factors, such as the administration of ulinastatin, statins, and phosphocreatine, remain to be elucidated.

Therefore, the aim of this study was to evaluate the incidence, risk factors, and the presence of any preventive factors in the development of CSA-AKI in Chinese patients according to the KDIGO classification.

Materials and Methods
=====================

Data collection
---------------

This retrospective cohort study included 2,575 patients ≥18 years of age who underwent cardiac surgery with cardiopulmonary bypass and were admitted to the cardiac intensive care unit at Nanjing First Hospital in Nanjing, China, between January 2008 and December 2013. The preoperative baseline serum creatinine (Scr) values were defined as the most recent Scr (μmol/L) detected within 7 days before the surgery. The exclusion criterion was end-stage kidney disease requiring renal replacement therapy.

This study complied with the Declaration of Helsinki and was approved by the Regional Human Research Ethics Committee of Nanjing First Hospital without the need for informed consent, on the condition that the subjects\' identities be removed before analysis due to this study being a retrospective analysis.

The KDIGO classification was applied to define AKI as either or both an increase in SCr ≥0.3 mg/dL (≥26.5 μmol/L) within 48 hours or an increase in SCr ≥1.5 times the baseline value, known or presumed to have occurred within the prior 7 days.

The demographics and intraoperative and postoperative data were collected from an electronic medical record database. The serum creatinine level was recorded each day until the 7th day after surgery. The patients who received a dose of ulinastatin 500,000 KIU intravenously in 50 mL saline for 15 minutes after induction of anesthesia were also identified. The surgery procedures included coronary artery bypass grafting (CABG) with CPB, valve surgery, and combined CABG and valve surgery.

Data analysis
-------------

The data were analyzed using the SPSS software package (ver. 21.0, SPSS, Chicago, USA). Continuous variables following a normal distribution were presented as the mean ± standard deviation and categorical variables as a percentage. An unpaired t-test was used to compare the means between two groups, and the chi-squared test was used to compare the proportions between two groups of subjects. The Mann-Whitney U test was used to compare medians.

Univariate binary logistic regression was performed to evaluate the potential modifiable risk factors associated with AKI. All of the potential covariates determined in a univariate analysis (p\<0.05) were entered in the final model. Multiple binary logistic regression with a backwards stepwise method was used to determine risk or protective factors for AKI (AKI vs. non-AKI). The significance and removal levels for a covariate were set at 0.05 and 0.1, respectively. The data were listed as the odds ratios (ORs) with 95% confidence intervals (CIs). The impact of AKI and the need for renal replacement therapy on the mortality of ICU and hospital length of stay were evaluated using multiple Cox-proportional hazards modeling. The data were expressed as hazard ratios (HRs) with 95% CI and p values. The influence of different KIDGO stages on the probability of 30-day hospital mortality was determined using a Kaplan-Meir survival analysis.

Results
=======

AKI incidence, patient characteristics, and patient outcomes
------------------------------------------------------------

A total of 2,808 patients who underwent cardiac surgery with cardiopulmonary bypass between January 2008 and December 2014 in our center were selected for our study, and 2,575 of them met the inclusion criteria and were entered into the final analysis. The postoperative CSA-AKI incidence was 36% (931 of 2,575). The demographic data and clinical characteristics of the study population are described in [Table 1](#t001){ref-type="table"}. The mean age at cardiac surgery was 56.0±13.9years, with 52.7% men. Patients who developed AKI were more likely to be men, were older, and had higher BMI (p\<0.01). Those with AKI more frequently had a history of hypertension (p\<0.001) and a history of diabetes mellitus (p=0.003), especially insulin-controlled diabetes (p\<0.001), compared with those who did not have AKI.

###### 

Patient Characteristics and Preoperative Variables.

  Variable                                                      All patients (n=2,575)   \>AKI (n =931)    Non AKI (n =1,644)   p
  ------------------------------------------------------------- ------------------------ ----------------- -------------------- ---------
  Age (y)                                                       56.0±13.9                57.6±13.3         55.1±14.1            \<0.001
  Male, n (%)                                                   1,356(52.7)              555(59.6)         801(48.7)            \<0.001
  BMI(kg/m^2^)                                                  23.6±3.6                 24.1±3.8          23.3±3.5             \<0.001
  **Baseline**                                                                                                                  
  History of hypertension,n(%)                                  847(32.3)                396(42.5)         451(27.4)            \<0.001
  History of diabetes,n(%)                                      265(10.3)                118(12.7)         147(10.0)            0.003
  Insulin-controlled diabetes,n(%)                              156(6.1)                 77(8.3)           79(4.8)              \<0.001
  COPD, n (%)                                                   47(1.8)                  21(2.3)           26(1.6)              0.220
  Acute myocardial infarction,n(%)                              86(3.3)                  29(3.1)           57(3.5)              0.633
  Chronic kidney disease, n (%)                                 41(1.6)                  18(1.9)           23(2.0)              0.298
  Cerebrovascular disease, n (%)                                123(4.8)                 53(5.7)           70(4.3)              0.101
  Coronaryangiography, n (%)                                    977(34.1)                325(34.9)         552(33.6)            0.493
  Ejection fraction (%)                                         59.3±8.8                 58.6±9.1          59.8±8.2             0.001
  Urgent surgery, n(%)                                          19(0.7)                  10(1.1)           9(0.55)              0.207
  Creatinine (μmol/L)                                           76.6±32.3                80.4±39.9         74.6±27.2            \<0.001
  Administration of statins, n (%)                              631(24.5)                238(25.6)         393(23.9)            0.347
  Phosphocreatine, n (%)                                        2,345(91.1)              854(91.7)         1,491(91.7)          0.376
  **Intraoperative**                                                                                                            
  CPB duration (min)                                            110.0±48.4               121.5±57.7        102.±40.5            \<0.001
  Aortic cross-clamp time (min)                                 73.3±36.2                80.0±38.9         69.4±33.9            \<0.001
  MAP (mmHg)                                                    62.3±7.1                 62.2±7.2          62.2±7.3             0.696
  Red blood cells transfused,(U)                                4.6±4.6                  5.9±5.9           3.9±3.5              \<0.001
  Need for cardioversion, n (%)                                 771(29.9)                298(32.0)         473(28.8)            0.085
  Mannitol, n (%)                                               2,273(88.3)              837(89.9)         1,435(87.3)          0.048
  Ulinastatin, n (%)                                            2,045(80.0)              710(76.3)         1,335(81.2)          0.003
  Hydroxyethyl starch, n (%)                                    1,977(76.8)              728(78.2)         1,249(76.0)          0.199
  Nasopharyngeal temperature during thelowest flow ofCPB (℃)    28.4±0.2                 28.2±0.2          28.7±0.3             \<0.001
  Hematocrit                                                    23.7±6.1                 23.8±5.2          23.5±4.6             0.179
  **Postoperative**                                                                                                             
  Mechanical ventilation (h), median(IQR)                       7.8(5.5to 10.7)          8.8(6.0to 12.7)   7.3(5.2to 9.7)       \<0.001
  Lactic acid (mmol/L)                                          2.26 ±1.79               2.47± 2.13        2.14 ±1.55           \<0.001
  Body temperature within 3 days after surgery (\>38℃), n (%)   1,003(39.0)              395(42.4)         608(37.0)            0.006
  NSAIDs, n(%)                                                  855(33.2)                298(32.0)         557(33.9)            0.332
  **Outcomes**                                                                                                                  
  RRT, n (%)                                                    30(1.2)                  30(3.2)           \-                   \<0.001
  In-hospital mortality, n (%)                                  38(1.5)                  24(2.6)           14(0.9)              0.001
  ICU LOS, days \[median (range)\]                              2(1to2)                  2(1to3)           2(1to2)              \<0.001
  Hospital LOS, days \[median (range)\]                         20(17to24)               21(17to26)        20(17to24)           \<0.001

The patients who experienced AKI had higher creatinine levels (p\<0.001), a lower ejection fraction (p=0.001), a longer cardiopulmonary bypass time (p\<0.001), a longer mechanical ventilation time (p\<0.001), a longer aortic cross-clamp time (p\<0.001), more RBC units transfused during surgery (p\<0.001), a lower nasopharyngeal temperature during CPB (p\<0.001), higher lactic acid levels (p\<0.001), a more frequent high body temperature (\>38℃) within 3 days after surgery (p=0.006), a more frequent use of mannitol (p=0.048), and a less frequent use of ulinastatin (p=0.003) than those without AKI. RRT rate was1.2% (30 of 2,575), and the overall in-hospital mortality rate was 1.5% (38 of 2,575). Patients who developed CSA-AKI had higher chances of in-hospital mortality rate than those who did not have AKI (2.6% vs. 0.9%, p=0.001). AKI was more likely to occur in men than in women (52.0% vs. 48.7, p\<0.001). The subgroup analysis of the subjects who developed AKI revealed higher frequencies of coronary heart disease (42.34% vs. 29.26% p\<0.01), hypertension (52.79% vs. 32.71%, p\<0.001), and diabetes mellitus (14.77% vs. 12.77%, p=0.386) in men than in women.

Patients with CSA-AKI had a longer length of hospital stay than patients without AKI (median 21 vs. 20 days, p\<0.001). Despite having a similar median length of stay in the ICU, a statistically significant difference was noted in the value between the AKI and non-AKI group \[median (range), 2 (1-3) vs. 2 (1-2) days, p\<0.001\].

Potential risk or protective factors for CSA-AKI in aunivariate analysis
------------------------------------------------------------------------

A univariate analysis for identifying the risk or protective factors of AKI and the results are listed in [Table 2](#t002){ref-type="table"}. The results showed that the following variables were associated with the development of AKI: age, male gender, BMI, history of hypertension, history of diabetes mellitus, insulin-controlled diabetes, creatinine \>88.4 μmol/L, cardiopulmonary bypass time, aortic cross-clamp time, RBC transfusion during surgery, nasopharyngeal temperature during the lowest flow of CPB, mechanical ventilation duration, lactic acid ≥2 mmol/L, body temperature (\>38℃) within 3 days after surgery. The administration of ulinastatin during surgery had an inverse association with CSA-AKI.

###### 

The Results of a Univariate Analysis for Determining the Risk Factors for AKI.

  Variable                                                 Odds ratio   95%CI         p
  -------------------------------------------------------- ------------ ------------- ---------
  Age (≥ 65 vs.\<65years)                                  1.367        1.145-1.632   0.001
  Male gender                                              1.553        1.320-1.828   \<0.001
  BMI                                                      1.335        1.184-1.504   \<0.001
  **Baseline**                                                                        
  History of hypertension                                  1.958        1.653-2.319   \<0.001
  History of diabetes mellitus                             1.478        1.143-1.911   0.003
  Insulin-controlled diabetes                              1.786        1.291-2.472   \<0.001
  COPD                                                     1.436        0.083-2.567   0.222
  AMI                                                      1.108        0.720-1.703   0.641
  History of chronic kidney disease                        1.389        0.746-2.588   0.300
  Cerebrovascular disease                                  1.357        0.941-1.958   0.102
  Coronaryangiography                                      1.061        0.896-1.257   0.493
  Ejection fraction (≥35% vs. \<35%)                       1.875        0.995-3.532   0.052
  Creatinine (\>88.4μmol/L)                                3.429        1.926-6.107   \<0.001
  Statins                                                  1.091        0.906-1.314   0.356
  Phosphocreatine                                          1.138        0.855-1.516   0.376
  **Intraoperative**                                                                  
  CPB duration (≥110 vs. \<110min)                         1.646        1.388-1.952   \<0.001
  Aortic cross-clamp time (≥60 vs. \<60min)                1.305        1.095-1.556   0.003
  MAP (≤60 vs. \>60mmHg)                                   1.182        0.966-1.446   0.104
  RBCs transfused                                          1.009        1.077-1.121   \<0.001
  Need for cardioversion                                   0.839        0.702-1.003   0.054
  Mannitol                                                 0.194        0.020-1.872   0.156
  Ulinastatin                                              0.712        0.578-0.877   0.001
  Hydroxyethyl starch                                      0.973        0.757-1.251   0.832
  Nasopharyngeal temperature during lowest flow of CPB     1.660        1.391-1.980   \<0.001
  Haematocrit (≤20 vs.\>20min)                             1.011        0.993-1.029   0.233
  **Postoperative**                                                                   
  Mechanical ventilation (≥9 vs.\<9h)                      1.869        1.585-2.205   \<0.001
  Lactic acid (≥2 vs.\<2mmol/L )                           1.198        1.017-1.412   0.030
  Body temperature (\>38 °C) within 3 days after surgery   1.252        1.063-1.475   0.007
  Administration of NSAIDs                                 0.919        0.774-1.091   0.332

In a multivariate logistic regression analysis ([Table 3](#t003){ref-type="table"}), the variables found to be statistically significant in the univariate analysis were all entered as determinants of AKI. The independent risk factors for CSA-AKI were male gender (OR, 1.41, 95% CI, 1.17-1.71 p\<0.001), BMI (OR, 1.29, 95%CI, 1.11-1.49, p=0.001), history of hypertension (OR, 1.49, 95% CI, 1.21-1.84, p\<0.001), insulin-controlled diabetes (OR, 1.56, 95% CI, 1.06-2.30, p=0.025), RBC units transfused (OR, 1.08, 95% CI, 1.05-1.11, p\<0.001), CPB duration ≥110 minutes (OR1.31, 95% CI, 1.07-1.61, p=0.009), mechanical ventilation time ≥9 hours (OR, 1.45, 95% CI, 1.20-1.75, p\<0.001), and body temperature (\>38℃) within 3 days after surgery (OR, 1.23, 95% CI, 1.02-1.50, p=0.032). Notably, the administration of ulinastatin was found to be beneficial for protecting against CSA-AKI development (OR, 0.69, 95% CI, 0.56-0.88, p=0.006) after adjustment for age, gender, BMI, history of hypertension, insulin-controlled diabetes, blood units transfused, CPB duration, and mechanical ventilation time.

###### 

The Results of a Multivariable Analysis Examining the Covariate Factors Associated with AKI Development.

  Variable                                               Odds ratio   95 % CI     p
  ------------------------------------------------------ ------------ ----------- ---------
  Male gender                                            1.41         1.17-1.71   \<0.001
  BMI                                                    1.29         1.11-1.49   0.001
  History of hypertension                                1.49         1.21-1.84   \<0.001
  Insulin-controlled diabetes                            1.56         1.06-2.30   0.025
  Creatinine (\>88.4μmol/L)                              1.87         0.94-3.72   0.074
  Nasopharyngeal temperature during CPB                  1.22         0.97-1.53   0.090
  Red blood cells transfused                             1.08         1.05-1.11   \<0.001
  CPB duration ≥110min                                   1.31         1.07-1.61   0.009
  Mechanical ventilation ≥9h                             1.45         1.20-1.75   \<0.001
  Ulinastatin administration                             0.69         0.56-0.88   0.006
  Body temperature (\>38℃) within 3 days after surgery   1.23         1.02-1.50   0.032

AKI and the need for RRT are risk factors for mortality
-------------------------------------------------------

Kaplan-Meir survival curves ([Figure](#g001){ref-type="fig"}) showed that KIDGO stage 2-3 AKI was associated with an increased 30-day mortality risk compared with stage 0 (chi-square: 12.28, p\<0.001; 242.05, p\<0.001, respectively), while no significant association was found with stage 1 (chi-square: 0.762, p=0.383).

![A Kaplan-Meir curve of the overall survival for the patients divided into four groups according to the KDIGO classification.](1349-7235-56-0275-g001){#g001}

The multivariable Cox proportional hazards model analysis revealed that AKI was an independent predictor of in-hospital mortality (unadjusted and adjusted HR: HR 2.14, 95%CI, 1.13-4.08, p=0.02; HR 3.16, 95%CI, 1.38-7.20, p=0.006, respectively), not of ICU mortality. The need for RRT was an independent risk factor for both ICU and in-hospital mortality (unadjusted and adjusted HR: HR 5.97, 95%CI 2.59-13.76, p\<0.001; HR 8.31, 95%CI, 2.98-23.18, p\<0.001, respectively) and in-hospital length of stay mortality (unadjusted and adjusted HR: 18.74, 95%CI, 8.66-40.55, p\<0.001; HR 23.86, 95%CI 9.31-60.15, p\<0.001) ([Table 4](#t004){ref-type="table"}).

###### 

The Influence of AKI and RRT on the Length of the ICU Stay and the Length of the Hospital Stay.

  -------------- -------------------------------------- ------------------------------------ -------------------- ------------------------
  **Variable**   **Unadjusted hazard ratio (95% CI)**   **Adjusted hazard ratio (95% CI)**                        
  ICU LOS        Hospital LOS                           ICU LOS                              Hospital LOS         
  AKI            1.28(0.64-2.54)                        2.14(1.13-4.08) \*                   2.10 (0.842-5.224)   3.16(1.38-7.1984) \*
  RRT            5.97(2.59-13.76) ^\#^                  18.74(8.66-40.55) ^\#^               8.31 (2.98-23.18)    23.86(9.31-60.15) ^\#^
  -------------- -------------------------------------- ------------------------------------ -------------------- ------------------------

\*p\<0.05, ^\#^p\<0.001; Adjusted for age, gender, BMI, mechanical ventilation time, and CPB duration.

Discussion
==========

In the present study we investigated the incidence of AKI, as defined by the KDIGO classifications, in patients after cardiac surgery and evaluated the impact of AKI on 30-day mortality rates. We also identified the potential risk factors and preventive factors for AKI. In contrast to previous studies, our main findings were that a body temperature greater than 38℃ within 3 days after cardiac surgery was an independent risk factor, while the administration of ulinastatin played a beneficial role in the development of AKI.

Our results demonstrated that the postoperative AKI incidence of cardiac surgery was 36%, conflicting with a previous finding of 8.9% ([@B13]), and 39% ([@B16]) based on AKIN criteria, 31% ([@B17]) according to RIFLE criteria, and 14% ([@B18]) based on the KDIGO criteria. The 1.2% rate of requiring renal replacement therapy is consistent with the 1-5% previously reported ([@B19]). The mortality rate was 1.5%, which is similar to the reported 1.4% ([@B17]). We found that patients with CSA-AKI had a higher hospital mortality rate, longer length of ICU stay and longer length of hospital of stay than patients who did not have CSA-AKI.

Our data demonstrated that KDIGO stages 2 and 3 were associated with a significant increase in the overall 30-day mortality compared with stage 0, while no significance was found between stages 1 and 0. Furthermore, the patients needing RRT had a significantly higher risk of mortality than those who did not need RRT. Liotta ([@B20]) reported that even a minimal elevation in the postoperative serum creatinine values of \<0.3 mg/dL was associated with increased long-term mortality over 6 years of follow-up, but not with mortality within 30 days of surgery. In his study, AKI groups 2 (creatinine 0.3 to 0.5 mg/dL) and 3 (creatinine \>0.5 mg/dL) were strongly associated with increased mortality in both the short and long term. The slight discrepancy with our results is probably due to their use of different methods of classification from our own study.

Our study showed that men were more likely to experience AKI than women, which differs from the findings of Rosner\'s study ([@B21]) but concurs with the findings of other studies ([@B22],[@B23]). We observed a higher frequency of coronary heart disease, hypertension, and diabetes mellitus among men, suggesting that these factors may contribute to some extent to men being more likely than women to experience AKI. Our data revealed that RBC transfusion during surgery was an independent risk factor for AKI, which was in agreement with the findings of previous studies ([@B24]). However, although RBC transfusion was found to be associated with a high risk of AKI, the "ideal" transfusion thresholds in cardiac patients remain largely unknown ([@B25]). The mechanisms by which intraoperative RBC transfusions contribute to CSA-AKI have not been fully clarified, although one suggested mechanism involves the changes that occur to RBCs during storage, such as decreased deformability, depletion of ATP and 2,3-diphosphoglycerate, an inability to generate nitric oxide, increased adhesiveness to vascular endothelium, and an increase in the levels of potassium cytokines, iron, and free hemoglobin. These factors may lead to the impairment of oxygen delivery, the activation of oxidative stress, and the exacerbation of the inflammatory response, which eventually result in the kidney dysfunction ([@B26]).

Our results demonstrated that a CPB time longer than 110 minutes was an independent risk factor for CSA-AKI. The pathogenesis mechanism of CPB may cause an immuno-reactive state where neutrophils are activated and recruited in tissues, resulting in tissue edema and necrosis and subsequently causing the organ\'s dysfunction ([@B27]).

Our data showed that mechanical ventilation duration greater than 9 hours was an independent risk factor in the development of AKI. Recently, van den Akker et al. ([@B28]) found that mechanical ventilation exceeding 24 hours is related to a 3-fold risk of developing AKI in critically ill patients. Heringlake ([@B29]) analyzed the incidence of AKI in 584 subjects with different times to extubation, suggesting that the length of postoperative positive pressure ventilation is a significant risk factor for the development of CSA-AKI.

One of our main findings was that a body temperature greater than 38℃ within 3 days after cardiac surgery was significantly associated with the development of AKI. To our knowledge, this is the first study to identify the postoperative body temperature as a risk factor of CSA-AKI. Body temperature is a basic vital sign; both hyperthermia and hypothermia can lead to an imbalance in the metabolism. A postoperative fever is a common complication of cardiac operations using cardiopulmonary bypass ([@B30]). Our data showed that the post-operative fever (body temperature greater than 38℃) rate was 38.5% and an independent risk factor for CSA-AKI. Early postoperative fever (\>38℃ in the first 72 hours) is a common phenomenon and rarely caused by an infection ([@B31]). Systemic inflammatory responses commonly occur as postoperative complications in patients undergoing cardiac surgery with cardiopulmonary bypass ([@B32]), and one manifestation of such a response is an elevated body temperature, usually greater than 38℃. Inflammatory responses play a key role in the development of AKI after cardiac operations ([@B33]). Therefore, a postoperative fever should be properly managed in order to reduce the risk of CSA-AKI.

In a newly published review, Thiele ([@B34]) found that there are currently no effective prophylactic pharmacologic agents for preventing the development or reducing the risk of CSA-AKI. We tried to determine the influence of perioperative medications such as statins, phosphocreatine, ulinastatin, and NSAIDs on the development of AKI. The results showed no obvious protective effect of phosphocreatines on reducing the risk of AKI. Statins have been shown to have anti-inflammatory effects by reducing the levels of inflammatory cytokines as well as circulating microparticles, which are involved in inflammatory cell activation ([@B35]). However, whether or not the use of statins preoperatively can decrease the incidence of CSA-AKI remains controversial ([@B36]-[@B38]); further studies are therefore needed.

Of note, our data showed that the administration of ulinastatin during CPB played a protective role in reducing the risk of AKI after cardiac surgery by approximately 30%. Ulinastatin, a powerful protease inhibitor derived from human urine, has been proven to possess anti-inflammatory properties and protective effects in many organs such as lung, liver, and kidney ([@B39]). Nakanishi et al. ([@B40]) found that prepump administration of ulinastatin was effective in suppressing the elevation of interleukin-6 and interleukin-8 soon after coronary artery bypass grafting surgery with cardiopulmonary bypass in a prospective, randomized, double-blind, placebo-controlled study. A meta-analysis of randomized controlled trials also suggested the ulinastatin could significantly reduce the cytokine concentrations in patients undergoing cardiac surgery compared with those who received placebo ([@B32]). Compared with ulinastatin, aprotinin, a serine protease inhibitor derived from bovine lung tissue which has antifibrinolyticand anti-inflammatory effects ([@B41]), was mainly used to reduce perioperative bleeding and transfusion in cardiac surgery ([@B42]), but its renoprotectiverole is still controversial ([@B43]-[@B45]). In addition, the protective role of ulinastatin was also confirmed by a propensity score matched study ([@B46]). Further prospective, randomized, controlled trials are warranted to confirm the protective role of ulinastatin in the development of CSA-AKI.

Limitations
-----------

Several limitations associated with the present study warrant mention. First, our study is a retrospective, single-center study, making it prone to bias. Second, due to the lack of urine output values, only creatinine was employed to determine whether or not a patient met the AKI criteria. In addition, determining the presence of AKI based on the urine output is not very practical, due to the urinary catheters being usually removed around two days after surgery.

Conclusion
==========

Our study showed that, when the KDIGO definitionwas applied, CSA-AKI commonly occurred in adult patients who underwent cardiac surgery with CPB and was associated with in-hospital mortality and a longer length of ICU and hospital stay. Mechanical ventilation duration, RBC transfusions during surgery, and a postoperative body temperature greater than 38℃ within 3 days after surgery were found to be independent risk factors for CSA-AKI. Our findings suggest that effective and proper management of these modifiable risk factors may decrease the risk of developing AKI in this setting. Furthermore, the administration of ulinastatin may be beneficial for patients undergoing cardiac surgery.
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